Penumbra Reports Strong Q2 2026 Growth Amid Boston Scientific Acquisition
Event summary
- Penumbra reported $390.0 million in Q2 2026 revenue, up 14.9% YoY.
- Thrombectomy revenue grew 12.5% YoY to $259.0 million, while embolization and access revenue surged 20.0% YoY to $131.1 million.
- Gross profit margin improved by 1.9 percentage points to 67.9%.
- Net income was $34.8 million, down from $45.3 million in Q2 2025 due to acquisition-related expenses.
The big picture
Penumbra's Q2 2026 results highlight its strong market position in thrombectomy and embolization technologies. The pending acquisition by Boston Scientific signals a strategic shift, potentially expanding Penumbra's reach within the broader medical device sector. Investors will be watching how the integration unfolds and whether the combined entity can drive further innovation.
What we're watching
- Acquisition Integration
- How Boston Scientific will integrate Penumbra's operations and whether the deal closes as expected.
- Revenue Diversification
- Whether Penumbra can sustain strong growth in embolization and access products alongside its core thrombectomy business.
- Operational Efficiency
- The pace at which Penumbra can control operating expenses amid the acquisition process.
Related topics